10/18/2007

Baxter International has received global rights to create and market an enzyme that helps blood clot. ADAMTS13 will treat thrombotic thrombocytopenic purpura and other blood-clotting disorders and could be evaluated for other indications, the company said.

Full Story:
Forbes

Related Summaries